TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33126096
Drug: Training healthcare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training healthcare workers as change agents in a Social and Behavioural Change Communication workshop, supported by a social marketing campaign.
Study: 32941094
Drug: Control without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control without surface treatment (Groups 1 & 5)
Study: 33000478
Drug: Additional 10
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional 10 minutes of 1-on-1 instruction by a trained physical therapy student or dental faculty member
Study: 35452688
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion amiodarone
Study: 36459908
Drug: Topical olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical olive oil dressing plus standard care (wound irrigation with normal saline and oral antibiotics) for four weeks
Study: 33793110
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (tamsulosin hydrochloride 0.2 mg nightly)
Study: 33793110
Drug: Medication (tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (tamsulosin hydrochloride 0.2 mg nightly)
Study: 34739450
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg/hour)
Study: 34739450
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg/hour)
Study: 33252241
Drug: Equine-Assisted Activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-Assisted Activity (EAA) program, 40 minutes twice a week for 16 weeks (32 sessions)
Study: 34564020
Drug: Nintedanib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (150 mg twice daily)
Study: 33740344
Drug: Transforaminal (TF)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal (TF) cervical epidural steroid injection
Study: 33740344
Drug: Parasagittal interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasagittal interlaminar (IL) cervical epidural steroid injection
Study: 36226676
Drug: 60-min massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-min massage doses
Study: 36226676
Drug: 30-min massage
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-min massage doses
Study: 36226676
Drug: 15-min massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min massage doses
Study: 36226676
Drug: 3×/week massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3×/week massage doses
Study: 36226676
Drug: 15-min doses
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-min doses
Study: 34491142
Drug: Frenotomy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frenotomy for PTT (surgical treatment arm, n = 24)
Study: 34928182
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion (ILE)
Study: 33657762
Drug: Neurogenic acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurogenic acupoint dry cupping therapy plus lifestyle modifications for 8 weeks
Study: 35620204
Drug: AI technology
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AI technology combined with ultrasound-guided needle knife interventional therapy
Study: 36215289
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus pemetrexed-based chemotherapy
Study: 33108484
Drug: Low-concentration peptide-HAP
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration peptide-HAP suspension (0.5 wt% HAP; Curodont, Credentis)
Study: 33108484
Drug: High-concentration peptide-HAP
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration peptide-HAP suspension (6.25% HAP; Curodont Protect)
Study: 33108484
Drug: Commercial bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial bleaching agent (VivaStyle Paint on Plus, VS, Ivoclar Vivadent)
Study: 32753571
Drug: Barbed suturing
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbed suturing of the joint capsule (group B)
Study: 32289474
Drug: 15 day
Normalized name: Tudorza Pressair 15 Day 400mcg/actuation Powder for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 day hypofractionated PMRT regimen (3.33 Gy daily to the chest wall and regional lymphatics in 11 fractions, with optional 4 fraction mastectomy scar boost)
Study: 35502503
Drug: High-volume TFEB
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume TFEB with steroids (group D)
Study: 35502503
Drug: High-volume TFEB
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume TFEB without steroids (group L)
Study: 32306987
Drug: Maintenance targeted
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance targeted therapy after chemotherapy
Study: 32306987
Drug: Agents with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents with a positive efficacy signal
Study: 35307550
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg CBD
Study: 35609202
Drug: Family planning
Normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family planning intervention (FP) including up to six counseling sessions, free transportation to FP clinic, free FP services, and treatment for contraceptive-related side effects.
Study: 35122952
Drug: Individual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual and group supportive therapy
Study: 33924645
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (150,000 IU) administered 24 hours before the run
Study: 33191598
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to antidepressant conspiracy theories (Study 3)
Study: 35466013
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy optimisation
Study: 32479786
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol dose escalation at 2 mg every 4 h
Study: 32479786
Drug: Neuroleptic rotation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic rotation with chlorpromazine at 25 mg every 4 h
Study: 32479786
Drug: Combined haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined haloperidol at 1 mg and chlorpromazine at 12·5 mg every 4 h
Study: 33037990
Drug: Once-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2
Study: 33037990
Drug: Twice-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly carfilzomib plus dexamethasone (Kd) 20/27 mg/m2
Study: 35133671
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg orally once daily for 24 weeks
Study: 32629112
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) antibiotic therapy
Study: 32629112
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) antibiotic therapy
Study: 32629112
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of antibiotic therapy
Study: 33421042
Drug: Clam Extract
Normalized name: clam allergenic extract
DrugBank: Quahog, unspecified (DB11009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clam Extract (CE) capsules, 3 times a day for 2 weeks
Study: 33421042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received empty capsules identical in appearance to CE capsules
Study: 34293124
Drug: DHA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (4 g/day for 4 weeks in the form of DHA-rich fish oil)
Study: 34293124
Drug: ALA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (4 g/day for 4 weeks in the form of ALA-rich flaxseed oil)
Study: 32096243
Drug: Delayed FGG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed FGG group (8 implants from control group)
Study: 35045327
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg once daily orally administered)
Study: 34137538
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Carbimazole (OD-CMZ)
Study: 34137538
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose of Carbimazole (DD-CMZ)
Study: 32076558
Drug: Newer generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer generation drug-eluting stents (simple stenting)
Study: 32076558
Drug: Newer generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer generation drug-eluting stents (complex stenting)
Study: 36226089
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) combined with conventional treatment
Study: 33218350
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus human menopausal gonadotropin (HMG) for endometrial preparation
Study: 33218350
Drug: Routine artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine artificial hormonal endometrial preparation
Study: 32801017
Drug: Oral THC:CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC:CBD cannabis extract (2.5 mg THC and 2.5 mg CBD, 1-4 self-titrated capsules, three times daily from days -1 to 5)
Study: 32801017
Drug: Oral THC:CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC:CBD cannabis extract
Study: 33219115
Drug: Eccentric exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercise therapy (EET)
Study: 32805185
Drug: Voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.2 mg 3 times daily
Study: 34500113
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment (SBRT with immunotherapy)
Study: 34500113
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (SBRT followed by immunotherapy)
Study: 32329037
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration (statin + group, 143 patients)
Study: 32329037
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin administration (statin - group, 201 patients)
Study: 32329037
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration (statin + group)
Study: 32329037
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin administration (statin - group)
Study: 32034447
Drug: 7-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-mg nicotine patch (NP)
Study: 32034447
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (PP)
Study: 36541117
Drug: Chemotherapy (C)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (C)
Study: 34454767
Drug: 2-scale combination
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-scale combination (0,1/2,3 or 0/1,2)
Study: 34773608
Drug: Inhaled Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Technosphere Insulin (TI) at doses of 10, 30, and 120 U
Study: 34773608
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin lispro (LIS) at doses of 8, 30, and 90 U
Study: 35471812
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg, amoxicillin 1000 mg, esomeprazole 40 mg, all twice daily for 14 days
Study: 35471812
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 240 mg twice daily, amoxicillin 1000 mg three times daily, esomeprazole 40 mg twice daily for 14 days
Study: 34155568
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg/day
Study: 35007940
Drug: ICDs exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICDs exposed to doses of 2, 5, or 10 Gy (6 MV) during radiation exposure
Study: 35007940
Drug: PMs exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMs exposed to doses of 2, 5, or 10 Gy (6 MV) during radiation exposure
Study: 35708557
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with lavender oil through inhalation and foot massage
Study: 32216468
Drug: Lactobacillus fermentum
Normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus fermentum CECT5716 (Lc40) administered to mothers (n=139); 1 capsule/day containing 3×10^9 cfu Lc40
Study: 32216468
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) capsule administered to mothers (n=152); 1 capsule/day
Study: 38508877
Drug: RAAS blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS blockers
Study: 32957418
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment, 12 sessions over 4 weeks
Study: 32957418
Drug: Manual acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual acupuncture (MA) treatment, 12 sessions over 4 weeks
Study: 32957418
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group, 20 mg fluoxetine orally per day for 4 weeks
Study: 32957418
Drug: Manual acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual acupuncture (MA) treatment
Study: 32330638
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg misoprostol
Study: 33509703
Drug: Standard-of-care basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care basal insulin (SOC-BI)
Study: 36215911
Drug: Video observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video observation of methadone take-home dosing
Study: 33634446
Drug: Restarting oral
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restarting oral anticoagulation within 14 days
Study: 33634446
Drug: Restarting oral
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restarting oral anticoagulation
Study: 34133836
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil plus SULT1A1 enzyme booster
Study: 34133836
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil plus placebo adjuvant
Study: 33573276
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of Pera orange juice
Study: 33573276
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of Moro orange juice
Study: 32539157
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention plus referral to treatment
Study: 32539157
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to treatment only
Study: 36347056
Drug: Integrase strand
Normalized name: Integrase strand transfer inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase strand transfer inhibitor therapy
Study: 36347056
Drug: Systemic inflammation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic inflammation, astrocyte activation, and tryptophan metabolism pathways
Study: 34489282
Drug: Standard informed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard informed consent (control arm) - includes full length trial PIS and administration of QuIC-A and QuIC-B.
Study: 35269639
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily gluten intake
Study: 33183258
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1.0 g by intravenous injection before tourniquet inflation and before surgical incision closure)
Study: 33183258
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3.0 g in 75 mL physiological saline 5 min prior to final tourniquet release)
Study: 35925043
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then as a single agent for adjuvant treatment.
Study: 35925043
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with chemotherapy for neoadjuvant treatment and then as a single agent for adjuvant treatment.
Study: 32139488
Drug: Oral felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral felodipine in patients with coeliac disease (Group A, B+C, D)
Study: 32139488
Drug: Oral felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral felodipine with grapefruit juice in healthy individuals
Study: 32139488
Drug: Oral felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral felodipine with water in healthy individuals
Study: 34251506
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (lopinavir-ritonavir and hydroxychloroquine)
Study: 32629035
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antiviral therapy)
Study: 2006134578
Drug: Anisodamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine 0.5 mg/(kg24 h) intravenously for 7 days
Study: 35339911
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) 10,000 lux
Study: 33241267
Drug: Sequential anti-tubercular
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential anti-tubercular treatment (ATT) regimen
Study: 32911505
Drug: Increased perceived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased perceived intrinsic cost of lying (treatment condition)
Study: 35914303
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.05% cyclosporine and artificial tears (CS group)
Study: 33721454
Drug: NIPS (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPS (oral S‐1 + intravenous and intraperitoneal chemotherapy with paclitaxel)
Study: 33721454
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral S‐1 + intravenous chemotherapy with oxaliplatin)
Study: 33721454
Drug: NIPS (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPS (after chemotherapy)
Study: 32086925
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles suspension injected into the thyroid gland of trial group patients.
Study: 32593895
Drug: HMB-enriched formula
Normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-enriched formula (calcium-HMB 1500 mg, L-arginine 7000 mg, L-glutamine 7000 mg per pack, 2 packs per day)
Study: 33499843
Drug: 4DryField® PH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4DryField® PH (5 g, subfascially and subcutaneously during wound closure)
Study: 34789504
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery during high-intensity exercise (HIE)
Study: 34789504
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery during moderate-intensity exercise (MIE)
Study: 34789504
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery during resistance exercise (RE)
Study: 32928851
Drug: Rhythm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm and Movement for Self-Regulation (RAMSR) intervention delivered by trained teachers during group time in kindergartens, daily for 8 weeks.
Study: 34498352
Drug: 12-week multimodal
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week multimodal exercise-based program including supervised exercise twice weekly, protein supplement, home-based walking program, nurse-led support and counseling
Study: 33555314
Drug: Rapid-tapering regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-tapering regimen (immediate high-dose daily administration of prednisone, 0.75 mg/kg, followed by rapid decrease)
Study: 33555314
Drug: Slow-tapering regimen
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-tapering regimen (gradual increase to 1.5 mg/kg every other day and slow decrease)
Study: 33555314
Drug: Rapid-tapering regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-tapering regimen
Study: 33555314
Drug: Slow-tapering regimen
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-tapering regimen